Netherlands-incorporated Mylan (Nasdaq: MYL) today announced the US launch of efavirenz tablets USP, 600mg.
Mylan says this is the first generic version of Bristol-Myers Squibb's (NYSE: BMY) Sustiva. The product is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) type 1 infection in adults and in pediatric patients at least three months old and weighing at least 3.5kg.
According to the Food and Drug Administration approval letter, Mylan was one of the first applicants to submit a substantially complete Abbreviated New Drug Application (ANDA) for efavirenz tablets USP, 600mg, containing a Paragraph IV certification, and is eligible for 180 days of generic drug exclusivity. The drug had US sales of around $113 million for the 12 months ending December 31, 2017, according to IQVIA data quoted by Mylan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze